Teva Pharmaceutical Industries. has filed a patent for a vial adaptor that improves the connection between a syringe and a vial. The adaptor includes a syringe connection port, a vial connection port with a skirt and spike, a conduit for fluid flow, and a valve for controlling fluid flow. The invention aims to provide a more efficient solution for connecting syringes and vials. GlobalData’s report on Teva Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Teva Pharmaceutical Industries, Cancer treatment biomarkers was a key innovation area identified from patents. Teva Pharmaceutical Industries's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
A vial adaptor for connecting a syringe and a vial
A recently filed patent (Publication Number: US20230310277A1) describes a vial adaptor that is designed to facilitate the reconstitution of drugs in vials. The vial adaptor includes a syringe connection port, a vial connection port with a skirt and a spike, and a conduit for fluid flow between the two ports. The adaptor also features a valve that can selectively block or allow fluid flow between the syringe and the vial connection port when the syringe is connected to the adaptor.
The valve in the vial adaptor is operated by a handle and can be moved in rotation between two positions. In the first position, the valve aligns with the conduit, allowing fluid flow, while in the second position, the valve blocks fluid flow. The valve can be operated independently of whether a syringe is connected to the adaptor.
The vial adaptor is designed with a cylindrical casing portion that houses the valve body, allowing it to rotate around a longitudinal axis. The longitudinal axis of the casing portion is orthogonal to the vial connection axis defined between the syringe connection port and the vial connection port.
The vial adaptor can be manufactured from a material that is resistant to aggressive solvents. It may also include a filter in the conduit and a septum to seal the conduit.
The patent also describes a method of using the vial adaptor, which involves connecting the adaptor to a vial and a syringe, selectively blocking or allowing fluid flow between the syringe and the vial using the valve, and performing various steps such as dispensing reconstitution fluid, agitating the vial, withdrawing the reconstituted solution, and performing subcutaneous injections.
The patent further mentions a system that includes the vial adaptor, a vial with a drug, and a syringe with a reconstitution fluid. The system may also include another syringe or needle for injections or administration.
Overall, this patent describes a vial adaptor with a valve mechanism that allows for controlled fluid flow during the reconstitution of drugs in vials. The adaptor is designed to be user-friendly and can be used in various medical settings.
To know more about GlobalData’s detailed insights on Teva Pharmaceutical Industries, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
